According to a new report published by Allied Market Research,
titled, "Antihyperlipidemic Drugs Market by Drug Class: Global Opportunity Analysis and Industry
Forecast, 2019–2026," the global antihyperlipidemic drugs market was
valued at $9,456 million in 2018, and is expected to reach $16,865 million by
2026, registering a CAGR of 7.5% from 2019 to 2026.
The rise in level of lipids in the blood is called as
hyperlipidemia. The drugs that are used to treat the condition are called
antihyperlipidemic drugs. Furthermore, there are major complications associated
with this condition such as heart attack. Therefore, the condition requires
early monitoring and treatment. Some of the antihyperlipidemic drugs available
in the market include statins, bile acid sequestrants, cholesterol, and
others.
Click Here
To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/6284
Sedentary lifestyle is a major factor that contributes to the
growth of antihyperlipidemic drugs market. Moreover, surge in incidence of
disorders related to distributed cholesterol levels in the blood also
contributes to the growth of the antihyperlipidemic drugs market. Moreover,
surge in awareness regarding complications related with hyperlipidemia is
another major factor that fuels the growth of the market. However, high cost of
the treatment is expected to hinder the market growth. Conversely, growth
opportunities exhibited by emerging economies is anticipated to offer lucrative
opportunities during the forecast period.
The antihyperlipidemic drugs market size is studied based on
segments, drug class, and region to provide a detailed assessment of the
market. Based on drug class, the market is divided into statins, PCSK9
inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric
acid derivatives, and combination. Based on region, it is analyzed across North
America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy,
Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South
Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of
LAMEA).
According to drug class, statins occupied the largest
antihyperlipidemic drugs market share in 2018, owing to surge in the incidence
of cardiovascular disorders. Furthermore, statins reduce the risk associated
with heart attacks, which is another major factor that contributes to the
growth of the market. Moreover, PCSK9 inhibitors segment is expected to
register the fastest growth during the forecast period, owing to the benefits
offered such as drastic reduction of LDL levels in the blood. The other factors
that boost the growth of the market include the surge in the geriatric
population and rise in healthcare expenditure across the globe. In addition,
the other factors which boost the growth of the market include the additional
benefits offered by the statins such as improved endothelial function, enhance
the stability of atherosclerotic plaques, and reduce the amount of inflammation
& damage done to cells due to oxidative stress.
In 2018, North America accounted for the major share of
antihyperlipidemic drugs market size, and is expected to remain dominant during
the forecast period, owing to easy availability of the antihyperlipidemic
drugs. Moreover, surge in the sedentary lifestyle is another major factor that
contributes to the growth of the market. Furthermore, surge in the obese
population is another major factor that fuels the growth of the
antihyperlipidemic drugs market. In addition, the presence of major key players
such as Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Merck & Co.,
Inc. and others is another major factor that fuels the growth of
antihyperlipidemic drugs market in the region. On the other side, Asia-Pacific
is estimated to register the fastest growth during the forecast period, owing
to surge in awareness related to the use of antihyperlipidemic drugs.
For
Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/6284
The developing economies offer lucrative opportunities for
antihyperlipidemic drugs providers to expand their business. The constantly
evolving life science industry drives the growth of the market in the
developing economies such as India, China, and others. Furthermore, this report
entails a detailed quantitative analysis along with the current global
antihyperlipidemic drugs market trends from 2019 to 2026 to identify the
prevailing opportunities along with the strategic assessment.
Key Findings of the
Study:
- Statins occupied one-third share
of the global antihyperlipidemic drugs market in 2018.
- The PCSK9 inhibitors segment is
anticipated to grow with the highest CAGR throughout the forecast period.
- The cholesterol absorption
inhibitors segment accounted for more than one-fourth share of the market
in 2018.
- Asia-Pacific is anticipated to
grow at the highest rate during the analysis period, followed by LAMEA.
